Product image of Lipanthyl (Fenofibrate) supplied by GNH India

Lipanthyl

Active Ingredient:
Fenofibrate
Origin:
EU

Lipanthyl (Fenofibrate)

Fenofibrate, the active ingredient in Lipanthyl, is a fibrate presented as an oral tablet formulation for oral administration. It is indicated for the management of elevated triglyceride and cholesterol concentrations in adult patients with dyslipidemia, contributing to the reduction of atherogenic lipid particles and associated cardiovascular risk.

GNH India supplies Lipanthyl as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, transplant centres and clinics worldwide, with established quality‑assured manufacturing and regulatory compliance, and reliable logistics support for global distribution.

Manufacturer / TM Owner

Viatris Medical

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Lipanthyl (fenofibrate) is used to treat lipid disorders by reducing triglyceride synthesis and enhancing fatty‑acid oxidation.

  • Hypertriglyceridemia: lowers very high triglyceride levels, helping to prevent pancreatitis.
  • Mixed dyslipidemia: reduces triglycerides and modestly increases HDL‑cholesterol while lowering LDL‑cholesterol.
  • Primary hypercholesterolemia: decreases total cholesterol and LDL‑cholesterol as part of combination therapy.

How It Works

  • Fenofibrate activates peroxisome proliferator‑activated receptor‑alpha (PPARα) in hepatocytes and peripheral tissues. Activation of PPARα up‑regulates genes involved in fatty‑acid β‑oxidation, enhances lipoprotein lipase activity, and suppresses apolipoprotein C‑III synthesis, leading to decreased hepatic triglyceride production and increased clearance of triglyceride‑rich lipoproteins from plasma.

Side Effects

Fenofibrate may be associated with a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects

  • Gastrointestinal discomfort: nausea, abdominal pain or dyspepsia.
  • Elevated liver enzymes: transient increase in ALT or AST.
  • Muscle pain: mild myalgia without weakness.
  • Headache: occasional tension‑type headache.
  • Skin reactions: rash or pruritus.

Serious or Rare Side Effects

  • Rhabdomyolysis: severe muscle breakdown with possible renal impairment.
  • Hepatotoxicity: marked elevation of liver enzymes or hepatitis.
  • Gallstones: formation of biliary sludge or stones.
  • Severe allergic reactions: anaphylaxis or angioedema.
  • Blood dyscrasias: thrombocytopenia or leukopenia.

Precautions & Warnings

Before initiating Lipanthyl, clinicians should consider several precautionary measures to ensure safe use.

  • Liver function: assess baseline hepatic enzymes and monitor periodically.
  • Renal function: evaluate kidney function, especially in patients with impairment.
  • Muscle disorders: avoid in patients with active myopathy or uncontrolled hypothyroidism.
  • Drug interactions: review concomitant medications that affect statin metabolism.
  • Pregnancy and lactation: use only if potential benefit justifies potential risk.
  • Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Avoid Interactions

Fenofibrate can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid)

  • Statins (especially high‑dose simvastatin): increased risk of rhabdomyolysis.
  • Anticoagulants (warfarin): potentiation of anticoagulant effect, requiring INR monitoring.
  • Bile acid sequestrants: may reduce fenofibrate absorption.

Moderate Interactions (Monitor Closely)

  • CYP2C8 inhibitors (e.g., gemfibrozil): increase fenofibrate plasma levels.
  • Immunosuppressants (e.g., cyclosporine): may elevate serum concentrations.
  • Oral contraceptives: possible alteration of lipid parameters.

Frequently Asked Questions

Lipanthyl contains fenofibrate and is prescribed to lower elevated triglyceride and cholesterol levels in patients with hypertriglyceridemia, mixed dyslipidemia, or primary hypercholesterolemia, helping to improve overall lipid profiles and reduce cardiovascular risk.

Fenofibrate activates the nuclear receptor PPARα, which increases the expression of genes involved in fatty‑acid oxidation, enhances lipoprotein lipase activity, and reduces production of triglyceride‑rich lipoproteins, thereby lowering plasma triglycerides and modestly improving HDL‑ and LDL‑cholesterol levels.

The appropriate dose of Lipanthyl is set by the prescribing clinician based on the patient’s specific lipid profile, renal and hepatic function, and any concomitant therapies. Dosage adjustments are individualized and should follow the prescriber’s instructions.

Safety data for fenofibrate in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To request Lipanthyl, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Unlike statins, which primarily lower LDL‑cholesterol, fenofibrate (Lipanthyl) mainly reduces triglycerides and modestly raises HDL‑cholesterol through PPARα activation. Both classes can be combined when needed, but the safety profile and drug‑interaction potential differ, requiring individualized assessment.

Lipanthyl should be stored at ambient temperature, preferably below 25 °C, in its original packaging. Keep the product away from moisture and direct light, and ensure the container is tightly closed to maintain stability.

Lipanthyl is taken orally, usually with a meal to improve absorption. The exact timing and whether it is taken once or twice daily depend on the prescriber’s instructions and the specific formulation supplied.

Serious adverse events include rhabdomyolysis, severe liver injury, gallstone formation, and rare hypersensitivity reactions such as anaphylaxis. Patients should report unexplained muscle pain, dark urine, jaundice, or signs of an allergic reaction promptly.

Lipanthyl is contraindicated in patients with known hypersensitivity to fenofibrate or any component of the formulation, active liver disease, severe renal impairment, and in individuals with pre‑existing muscle disorders such as myopathy.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Fenofibrate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT